Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quest PharmaTech has signed a collaborative research agreement with the BC Cancer Agency to develop a combination therapy for the treatment of lung cancer.
Subscribe to our email newsletter
The potential treatment will utilize the company’s lead oncology product, SL052, with various immunotherapeutic agents. Research has shown that photodynamic therapy (PDT) can augment the therapeutic effects of immunomodulators such as antibodies, antigens, cytokines and immunoadjuvants in cancer patients.
Under the terms of the agreement, the BCCA will investigate therapeutic and mechanistic aspects of anti-tumor effects achieved by combining PDT based on Quest’s photosensitizer, SL052, with various immunotherapeutic agents.